All In MedTech

FDA Clearance Tracker · P100044-S023

PROPEL CONTOUR SINUS IMPLANT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 23, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 23, 2017

Approved

Time to decision

206 days

Received Aug 1, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P100044-S023
Device name
PROPEL CONTOUR SINUS IMPLANT
Applicant location
Menlo Park, CA
Received
Aug 1, 2016
Decided
Feb 23, 2017
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P100044

Device type

Device class
Class III

Every decision under product code OWO

FDA's approval statement

As written in FDA's record.

Approval of the PROPEL Contour Sinus Implant. This device is indicated for use in patients greater than or equal to 18 years of age to maintain patency of the frontal and maxillary sinus ostia following sinus surgery and locally deliver steroids to the sinus mucosa. The PROPEL Contour Sinus Implant separates/dilates mucosal tissues, prevents obstruction by adhesions/scarring, and reduces edema. The implant reduces the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids.

Source documents

Other decisions for Intersect Ent.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.